GSK cancer vaccine misses target in melanoma trial

September 5, 2013 6:45 AM

12 0

GSK cancer vaccine misses target in melanoma trial

LONDON (Reuters) - An experimental cancer vaccine from GlaxoSmithKline failed to meet the first of two joint targets in a closely watched late-stage clinical trial, dealing a blow to the high-risk, high-reward project.

Britain's biggest drugmaker said on Thursday that it would continue with the Phase III trial of its MAGE-A3 therapeutic vaccine until the second of the targets, known as co-primary endpoints, is assessed.

Read more

To category page

Loading...